Impact of macrolide therapy on clinical outcomes in hospitalized pneumonia patients: a retrospective study from Lebanese hospitals
Open Access
- 4 December 2025
- journal article
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 43155
Abstract
Community-acquired pneumonia (CAP) poses a high burden on Lebanese hospitals, especially when patients require Intensive Care Unit (ICU) or prolonged length of stay. Macrolides are widely used for their antibacterial properties and also downregulate systemic inflammation. This retrospective cohort study examined 337 hospitalized patients with CAP in Lebanon between April 2011 and March 2025, comparing those who received macrolide with those who did not. Findings showed that, even after controlling for comorbidities, age, and inflammatory indicators, macrolide therapy was independently correlated with a significant reduction in mortality rate (adjusted OR = 0.26; p = 0.011). However, macrolides were not associated with reductions in ICU admission and length of stay. As for the inflammatory markers, levels of erythrocyte sedimentation rate (ESR), and procalcitonin (PCT) decreased significantly after macrolide treatment, but CRP did not. Subgroup analyses revealed fewer ICU admissions with azithromycin compared to clarithromycin, and with intravenous versus oral use, though these findings should be interpreted cautiously given the observational design. Overall, macrolide treatment, particularly azithromycin, may contribute to the improvement in survival of CAP patients, especially those with high inflammatory markers or comorbidities, which suggests potential benefit in using it in the context of a combination therapy. This result supports the rationale for using macrolides in combination therapy and emphasizes prospective studies to investigate their immunomodulatory properties in the management of pneumonia.Keywords
This publication has 66 references indexed in Scilit:
- ICU-acquired infections in immunocompromised patientsIntensive Care Medicine, 2024
- Association Between Initiation of Pulmonary Rehabilitation After Hospitalization for COPD and 1-Year Survival Among Medicare BeneficiariesJAMA, 2020
- Adverse events in people taking macrolide antibiotics versus placebo for any indicationCochrane Database of Systematic Reviews, 2019
- Effectiveness of β-Lactam Monotherapy vs Macrolide Combination Therapy for Children Hospitalized With PneumoniaJAMA Pediatrics, 2017
- Incidence, Risk Factors, and Attributable Mortality of Secondary Infections in the Intensive Care Unit After Admission for SepsisJAMA, 2016
- β-Lactam Monotherapy vs β-Lactam–Macrolide Combination Treatment in Moderately Severe Community-Acquired PneumoniaJAMA Internal Medicine, 2014
- Association of Azithromycin With Mortality and Cardiovascular Events Among Older Patients Hospitalized With PneumoniaJAMA, 2014
- Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adultsCochrane Database of Systematic Reviews, 2012
- Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseasesEuropean Journal of Clinical Pharmacology, 2011
- Effect of Macrolides as Part of Initial Empiric Therapy on Length of Stay in Patients Hospitalized With Community-Acquired PneumoniaArchives of internal medicine (1960), 1999